Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion

Inclusion Criteria: * 1.Age ≥18 years and ≤80 years * 2.Symptoms and signs consistent with anterior circulation ischemia; * 3.Computed tomography angiography (CTA) /magnetic resonance angiography (MRA) /digital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1/M2 segments of the middle cerebral artery (MCA M1/M2); * 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment; * 5.Premorbid mRS ≤1; * 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW); * 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission; * 8.ASPECTS ≥3; * 9.Informed consent obtained from the patient or his/her legal representative. Exclusion Criteria: * 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres. * 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation; * 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS; * 4.Bilateral dilated pupils; * 5.Allergy to GM1 or excipients; * 6.Severe contrast allergy or absolute contraindication to iodinated contrast; * 7.Systolic pressure \>185 mmHg or diastolic pressure \>110 mmHg, and cannot be controlled by antihypertensive drugs; * 8.Blood glucose \<50 mg/dl (2.8 mmol/L) or \>400 mg/dl (22.2 mmol/L); * 9.Platelet \<50\*10\^9/L; * 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and INR \> 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours; * 11.Known Severe renal Failure as defined by a serum creatinine \> 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate (GFR) \<30, or patient requires hemodialysis or peritoneal dialysis; * 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.); * 13.Presumed vasculitis or septic embolization; * 14.Suspicion of aortic dissection; * 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs). * 16\. Significant mass effect causing midline shift. * 17\. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition; * 18.Females who are pregnant or in lactation; * 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases); * 20.Autoimmune diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome) * 21.Participating in other clinical trials that could confound the evaluation of the study; * 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.